MedDataX Logo

Breast Cancer Treatment Based on Organ-like Culture

NCT ID: NCT03925233

Last Updated: 2019-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-02

Study Completion Date

2021-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer

NCT06155305

Organoids Breast Cancer Neoadjuvant Chemotherapy
RECRUITING

Onco4D(TM) Biodynamic Chemotherapy Selection for Breast Cancer Patients

NCT03164863

Breast Cancer
UNKNOWN

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

NCT00003253

Breast Cancer
UNKNOWN PHASE2

Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient

NCT00669773

Breast Cancer
UNKNOWN PHASE2

Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

NCT00003953

Breast Cancer
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Organoids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HER2+ Breast Cancer

Trastuzumab

Intervention Type DRUG

Trastuzumab Injection

Doxorubicin Hydrochloride

Intervention Type DRUG

Doxorubicin Hydrochloride Injection

Epirubicin hydrochloride

Intervention Type DRUG

Epirubicin hydrochloride injection

Fluorouracil

Intervention Type DRUG

Fluorouracil injection

Paclitaxel

Intervention Type DRUG

Paclitaxel injection

Gemcitabine

Intervention Type DRUG

Gemcitabine injection

Cisplatin

Intervention Type DRUG

Cisplatin injection

Recombinant Human Endostatin

Intervention Type DRUG

Recombinant Human Endostatin Injection

Pirarubicin hydrochloride

Intervention Type DRUG

Pirarubicin hydrochloride injection

Pyrrolidine

Intervention Type DRUG

Pyrrolidine tablets

Ixabepilone

Intervention Type DRUG

Ixapilone Injection

Tamoxifen citrate

Intervention Type DRUG

Tamoxifen citrate tablets

Vinorelbine tartrate

Intervention Type DRUG

Vinorelbine tartrate injection

Carboplatin

Intervention Type DRUG

Carboplatin injection

Methotrexate

Intervention Type DRUG

Methotrexate injection

Eribulin mesylate

Intervention Type DRUG

Eribulin mesylate injection

Toremifene citrate

Intervention Type DRUG

Toremifene citrate tablets

Anastrozole

Intervention Type DRUG

Anastrozole tablets

Letrozole

Intervention Type DRUG

Letrozole tablets

Exemestane

Intervention Type DRUG

Exemestane tablets

Fulvestrant

Intervention Type DRUG

Fulvestrant injection

Olaparib

Intervention Type DRUG

Olapani pill

Bevacizumab

Intervention Type DRUG

Bevacizumab injection

Apatinib mesylate

Intervention Type DRUG

Apatinib mesylate tablets

Pattozumab

Intervention Type DRUG

Pattozumab injection

Capecitabine

Intervention Type DRUG

Capecitabine tablets

Ear particles

Intervention Type DRUG

Ear particles

Aidi Injection

Intervention Type DRUG

Aidi Injection

Cyclophosphamide

Intervention Type DRUG

Cyclophosphamide injection

ER+ Breast Cancer

Trastuzumab

Intervention Type DRUG

Trastuzumab Injection

Doxorubicin Hydrochloride

Intervention Type DRUG

Doxorubicin Hydrochloride Injection

Epirubicin hydrochloride

Intervention Type DRUG

Epirubicin hydrochloride injection

Fluorouracil

Intervention Type DRUG

Fluorouracil injection

Paclitaxel

Intervention Type DRUG

Paclitaxel injection

Gemcitabine

Intervention Type DRUG

Gemcitabine injection

Cisplatin

Intervention Type DRUG

Cisplatin injection

Recombinant Human Endostatin

Intervention Type DRUG

Recombinant Human Endostatin Injection

Pirarubicin hydrochloride

Intervention Type DRUG

Pirarubicin hydrochloride injection

Pyrrolidine

Intervention Type DRUG

Pyrrolidine tablets

Ixabepilone

Intervention Type DRUG

Ixapilone Injection

Tamoxifen citrate

Intervention Type DRUG

Tamoxifen citrate tablets

Vinorelbine tartrate

Intervention Type DRUG

Vinorelbine tartrate injection

Carboplatin

Intervention Type DRUG

Carboplatin injection

Methotrexate

Intervention Type DRUG

Methotrexate injection

Eribulin mesylate

Intervention Type DRUG

Eribulin mesylate injection

Toremifene citrate

Intervention Type DRUG

Toremifene citrate tablets

Anastrozole

Intervention Type DRUG

Anastrozole tablets

Letrozole

Intervention Type DRUG

Letrozole tablets

Exemestane

Intervention Type DRUG

Exemestane tablets

Fulvestrant

Intervention Type DRUG

Fulvestrant injection

Olaparib

Intervention Type DRUG

Olapani pill

Bevacizumab

Intervention Type DRUG

Bevacizumab injection

Apatinib mesylate

Intervention Type DRUG

Apatinib mesylate tablets

Pattozumab

Intervention Type DRUG

Pattozumab injection

Capecitabine

Intervention Type DRUG

Capecitabine tablets

Ear particles

Intervention Type DRUG

Ear particles

Aidi Injection

Intervention Type DRUG

Aidi Injection

Cyclophosphamide

Intervention Type DRUG

Cyclophosphamide injection

Triple Negative Breast Cancer

Trastuzumab

Intervention Type DRUG

Trastuzumab Injection

Doxorubicin Hydrochloride

Intervention Type DRUG

Doxorubicin Hydrochloride Injection

Epirubicin hydrochloride

Intervention Type DRUG

Epirubicin hydrochloride injection

Fluorouracil

Intervention Type DRUG

Fluorouracil injection

Paclitaxel

Intervention Type DRUG

Paclitaxel injection

Gemcitabine

Intervention Type DRUG

Gemcitabine injection

Cisplatin

Intervention Type DRUG

Cisplatin injection

Recombinant Human Endostatin

Intervention Type DRUG

Recombinant Human Endostatin Injection

Pirarubicin hydrochloride

Intervention Type DRUG

Pirarubicin hydrochloride injection

Pyrrolidine

Intervention Type DRUG

Pyrrolidine tablets

Ixabepilone

Intervention Type DRUG

Ixapilone Injection

Tamoxifen citrate

Intervention Type DRUG

Tamoxifen citrate tablets

Vinorelbine tartrate

Intervention Type DRUG

Vinorelbine tartrate injection

Carboplatin

Intervention Type DRUG

Carboplatin injection

Methotrexate

Intervention Type DRUG

Methotrexate injection

Eribulin mesylate

Intervention Type DRUG

Eribulin mesylate injection

Toremifene citrate

Intervention Type DRUG

Toremifene citrate tablets

Anastrozole

Intervention Type DRUG

Anastrozole tablets

Letrozole

Intervention Type DRUG

Letrozole tablets

Exemestane

Intervention Type DRUG

Exemestane tablets

Fulvestrant

Intervention Type DRUG

Fulvestrant injection

Olaparib

Intervention Type DRUG

Olapani pill

Bevacizumab

Intervention Type DRUG

Bevacizumab injection

Apatinib mesylate

Intervention Type DRUG

Apatinib mesylate tablets

Pattozumab

Intervention Type DRUG

Pattozumab injection

Capecitabine

Intervention Type DRUG

Capecitabine tablets

Ear particles

Intervention Type DRUG

Ear particles

Aidi Injection

Intervention Type DRUG

Aidi Injection

Cyclophosphamide

Intervention Type DRUG

Cyclophosphamide injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trastuzumab

Trastuzumab Injection

Intervention Type DRUG

Doxorubicin Hydrochloride

Doxorubicin Hydrochloride Injection

Intervention Type DRUG

Epirubicin hydrochloride

Epirubicin hydrochloride injection

Intervention Type DRUG

Fluorouracil

Fluorouracil injection

Intervention Type DRUG

Paclitaxel

Paclitaxel injection

Intervention Type DRUG

Gemcitabine

Gemcitabine injection

Intervention Type DRUG

Cisplatin

Cisplatin injection

Intervention Type DRUG

Recombinant Human Endostatin

Recombinant Human Endostatin Injection

Intervention Type DRUG

Pirarubicin hydrochloride

Pirarubicin hydrochloride injection

Intervention Type DRUG

Pyrrolidine

Pyrrolidine tablets

Intervention Type DRUG

Ixabepilone

Ixapilone Injection

Intervention Type DRUG

Tamoxifen citrate

Tamoxifen citrate tablets

Intervention Type DRUG

Vinorelbine tartrate

Vinorelbine tartrate injection

Intervention Type DRUG

Carboplatin

Carboplatin injection

Intervention Type DRUG

Methotrexate

Methotrexate injection

Intervention Type DRUG

Eribulin mesylate

Eribulin mesylate injection

Intervention Type DRUG

Toremifene citrate

Toremifene citrate tablets

Intervention Type DRUG

Anastrozole

Anastrozole tablets

Intervention Type DRUG

Letrozole

Letrozole tablets

Intervention Type DRUG

Exemestane

Exemestane tablets

Intervention Type DRUG

Fulvestrant

Fulvestrant injection

Intervention Type DRUG

Olaparib

Olapani pill

Intervention Type DRUG

Bevacizumab

Bevacizumab injection

Intervention Type DRUG

Apatinib mesylate

Apatinib mesylate tablets

Intervention Type DRUG

Pattozumab

Pattozumab injection

Intervention Type DRUG

Capecitabine

Capecitabine tablets

Intervention Type DRUG

Ear particles

Ear particles

Intervention Type DRUG

Aidi Injection

Aidi Injection

Intervention Type DRUG

Cyclophosphamide

Cyclophosphamide injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form

Exclusion Criteria

Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study.

Other investigators believe that patients who are not suitable for this study group
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xijing Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

JingSu

Xi'an, Shaanxi, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KY20182079-F-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
NCT03933319 UNKNOWN PHASE2
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023 RECRUITING NA
Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)
NCT01231022 COMPLETED
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00003927 COMPLETED PHASE1
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02003209 COMPLETED PHASE3
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
NCT00499083 COMPLETED PHASE2
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
NCT03994107 UNKNOWN PHASE1/PHASE2
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT00353483 RECRUITING
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
NCT00028873 COMPLETED PHASE2
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
NCT05914753 UNKNOWN NA
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
NCT05257395 ACTIVE_NOT_RECRUITING PHASE3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725 RECRUITING PHASE3
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
NCT05953168 NOT_YET_RECRUITING PHASE2
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
NCT00436566 COMPLETED PHASE2
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
NCT03373708 UNKNOWN PHASE2/PHASE3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337 RECRUITING PHASE3
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
NCT04290793 ACTIVE_NOT_RECRUITING PHASE2/PHASE3
AKT Inhibitor in Oestrogen Positive Breast Cancer
NCT02077569 COMPLETED PHASE2
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NCT00310089 COMPLETED NA
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344793 COMPLETED
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00003352 COMPLETED PHASE2
CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
NCT04059003 UNKNOWN
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
NCT02689921 UNKNOWN PHASE2
Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
NCT06658080 RECRUITING
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
NCT07093931 NOT_YET_RECRUITING PHASE4